Protective Effects of Berberine as A Natural Antioxidant and Anti-Inflammatory Agent Against Nephrotoxicity Induced by Cyclophosphamide in Mice

Mohammad Amin Mombeini

Ahvaz Jundishapur University of Medical Sciences: Ahvaz Jondishapour University of Medical Sciences

Hadi Kalantar

Ahvaz Jundishapur University of Medical Sciences: Ahvaz Jondishapour University of Medical Sciences

Elahe Sadeghi

Ahvaz Jundishapur University of Medical Sciences: Ahvaz Jondishapour University of Medical Sciences

Mehdi Goudarzi

Ahvaz Jundishapur University of Medical Sciences: Ahvaz Jondishapour University of Medical Sciences

Hamidreza Khalili

Ahvaz Jundishapur University of Medical Sciences: Ahvaz Jondishapour University of Medical Sciences

Mojtaba Kalantar (✉ kalantar-m@shoushtarums.ac.ir)

Ahvaz Jundishapur University of Medical Sciences: Ahvaz Jondishapour University of Medical Sciences

Research Article

Keywords: Cyclophosphamide, Berberine, Nephrotoxicity, Oxidative stress, Inflammation.

Posted Date: June 8th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-554294/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Naunyn-Schmiedeberg's Archives of Pharmacology on January 7th, 2022. See the published version at <https://doi.org/10.1007/s00210-021-02182-3>.

Abstract

Purpose

Cyclophosphamide is an alkylating agent with nephrotoxicity that constraints its clinical application. Berberine is an isoquinoline derivative alkaloid with biological functions like antioxidant and anti-inflammatory. The current research intended to examine the nephroprotective impacts of berberine against cyclophosphamide-stimulated nephrotoxicity.

Methods

Forty animal subjects were randomly separated into five categories of control (Group I). Cyclophosphamide (200 mg/kg, i.p., on 7th day) (Group II), and groups III and IV that received berberine 50 and 100 mg/kg orally for seven days and a single injection of cyclophosphamide on 7th day. Group V as berberine (100 mg/kg, alone). On day 8, blood samples were drawn from the retro-orbital sinus to determine serum levels of blood urea nitrogen (BUN), creatinine (Cr), Neutrophil gelatinase-associated lipocalin (NGAL), and kidney injury molecule-1 (KIM-1) as biomarkers for kidney injury. Nitric oxide (NO), malondialdehyde (MDA) and glutathione (GSH) levels, catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GPx) activities as oxidative stress factors, tumor necrosis factor- α (TNF- α) and interleukin 1 beta (IL-1 β) levels as inflammatory mediators were assessed in kidney tissue.

Results

The results of this study demonstrated that berberine was able to protect remarkably the kidney from CP-induced injury through decreasing the level of BUN, Cr, NGAL, KIM-1, NO, MDA TNF- α , IL-1 β and increasing the level of GSH, CAT, SOD and GPx activities.

Conclusion

Berberine may be employed as a natural agent to prevent cyclophosphamide-induced nephrotoxicity through anti-oxidant and anti-inflammatory effects.

Introduction

Cyclophosphamide (CP) is an alkylating agent that has been in clinical use for more than 60 years (Lawson et al., 2008). It's extensively used to treat various forms of malignancies such as lymphoma and breast cancer. Also, CP is widely used in organ transplantation, rheumatoid arthritis, multiple sclerosis, and etc., as an immunosuppressant (Crivellari et al., 2000; Perini et al., 2007). It's well-known that cyclophosphamide and its reactive metabolites such as phosphoramidate mustard and acrolein results in bladder acute inflammation as well as nephrotoxicity or hepatotoxicity,

which limits long-term using of CP in clinical practice(Rodriguez-Antona and Ingelman-Sundberg, 2006; Wahlang et al., 2015). There are evidence indicating the possible role of inflammatory pathways in negative consequences of cyclophosphamide and a number of researchers reported that CP enhances inflammatory markers including factor- α (TNF- α) and interleukin 1 beta (IL-1 β), and IL-6 in the organs(Hamsa and Kuttan, 2011). By contrast, recent studies have shown that oxidative stress (OS) also has a crucial impact on CP-induced nephrotoxicity(Stankiewicz et al., 2002). CP depletes reduced glutathione (GSH) as a protective antioxidant and increases OS factors like malondialdehyde (MDA) and nitric oxide (NO), CP also inhibits the activities of powerful antioxidant enzymes like glutathione peroxidase (GPx), superoxide dismutase (SOD) and catalase (CAT)(Kuo et al., 2004; Li et al., 2014). It seems both inflammatory and stress oxidative pathways play a role in CP-nephrotoxicity and several studies suggested that antioxidant and anti-inflammatory agents can be an important therapeutic approach to reduce CP-nephrotoxicity(Stankiewicz et al., 2002).

Berberine (BBR) is an isoquinoline derivative alkaloid isolated from many plant species like *Cortex phellodendron* (Huang bai), *Hydrastis canadensis* (goldenseal) and *Rhizoma coptidis* (Huanglian)(Kuo et al., 2004). Recently, an increase number of studies have revealed this compound has an extensive spectrum of biological functions such as antioxidant and anti-inflammatory(Li et al., 2014), anticancer(Sun et al., 2009) and anti-hyperglycemic(Mahmoud et al., 2017) effects. Studies have been shown that BBR attenuates the output of inflammatory mediators like TNF- α , IL-1 β , IL-6, and IL-8(Lou et al., 2011; Zhang et al., 2011; Zhang et al., 2016b). In addition, BBR seems to increase the cellular antioxidant defense machinery including increasing the activity of CAT, SOD, and GPx and decrease OS factors like protein carbonyl (PC) content, MDA and NO levels(Zhou and Zhou, 2011).

In this study, we utilized cyclophosphamide as an experimental model to study the possible impact of berberine as an antioxidant and anti-inflammatory agent on CP-induced nephrotoxicity.

Materials And Methods

Drug and Chemicals

Cyclophosphamide purchased from Roche chemical company (Grenzach, Germany). Berberine, reduced glutathione, tris-hydrochloric acid, bovine serum albumin (BSA), 2,2'-dinitro-5,5'-dithiodibenzoic acid (DTNB), oxidized glutathione, trichloroacetic acid (TCA), and 2-thiobarbituric acid (TBA) obtained from Sigma St. Louis.

Animal and Study Design

Forty male NMRI mice (25 $\pm$ 2 g) were purchased from the Experimental Animal Center Laboratory of Ahvaz Jundishapur University of Medical Sciences. The mice were kept in a room with 25 $\pm$ 2°C temperature in polycarbonate cages with a 12/12 cycle. In addition, food and water were available without any limitation. The investigation complies with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication no. 85-23, revised 1996). The

Animal Ethics Committee of the Ahvaz Jundishapur University of Medical Sciences approved our research protocol (**Ethic code:** IR.BHN.REC.1397.033).

Five experimental groups consisting of 8 randomly selected mice each were established:

Control group (I): 0.1 ml of normal saline (vehicle of BBR, p.o.) was administered for a week and one dose of 0.9% normal saline was injected (vehicle of CP, i.p.) on 7th day.

CP group (II): 0.1 ml of normal saline was administered for a week and one dose of CP (200mg/kg, i.p.) was injected on the 7th day.

Group III (CP + BBR 50): BBR (50 mg/kg, p.o.) was administered for a week and one dose of CP (200 mg/kg, i.p.) was injected on the 7th day.

Group IV (CP + BBR 100): BBR (100 mg/kg, p.o.) was administered for a week and one dose of CP (200 mg/kg, i.p.) was injected on the 7th day.

Group V (BBR group): BBR (100 mg/kg, p.o.) was administered for a week and one dose of normal saline 0.9% was injected on the 7th day.

The dose of CP and BBR was selected based on our previous studies and other studies(El-Naggar et al., 2015; Goudarzi et al., 2017). On 8th day, ketamine/xylazine (60/6 mg/kg, i.p) was used for performing anesthetized and then were sacrificed by fast decapitation. The retro-orbital sinus was selected for taking blood samples. All blood samples were centrifuged at 3000g for 10 min and kept at -20 °C until investigations. After removing and washing the kidneys with normal saline, the right kidney was fixed in 10% phosphate-buffer formalin for histological analysis. The left kidney was used for biochemical assays

Tissue homogenization and protein measurement

The left kidney weighed and homogenized (1/ 10 w/v) with a tissue homogenizer (Wisetis HG-150) for 60 minutes in ice-cold phosphate-buffered saline (PBS) solution (10 mM Na₂HPO₄, 10 mM KH₂PO₄, 0.9 g NaCl/100 mL, pH 7.4) and the clear supernatant was kept in -70 °C for further investigations. The total protein content in the clear supernatant of the kidney was estimated following the technique of Bradford(Bradford, 1976).

Analysis of serum biochemical parameters

The level of Serum biochemical marker blood urea nitrogen (BUN) and creatinine (Cr) were measured using the kits according to the protocol of the manufacturer (Pars Azmun. Co. Iran), and using an auto-analyzer (BT-TARGA-3000 model). BUN and Cr levels were expressed as mg/dL serum. Assessment of KIM-1 and NGAL levels were done using commercial kits (IBL-America (Immuno-Biological Laboratories).

Assay of MDA level

MDA in the kidney as a marker of lipid peroxidation was assayed via the TBA color reaction by Aust's technique (Goudarzi et al., 2021; Moore and Roberts, 1998). MDA content was expressed as nmol/mg protein.

Assay of GSH level

GSH in the kidney was measured by a modified version of Ellman's technique following the observation of a yellow complex with Ellman's (2, 2'-dinitro-5, 5'-dithiodibenzoic acid Reagent) (Kalantar et al., 2016; Riddles et al., 1979).

Assay of CAT activity

CAT function in the kidney was measured using Abebi's method (Aebi, 1984) using H_2O_2 as a substrate. Briefly, H_2O_2 was mixed and decomposition rate of H_2O_2 was evaluated through estimating the absorbance alternations at 240 nm for 60 seconds. An unit of catalase (CAT) function was considered as 1 μM of H_2O_2 that is decomposed in 1 minute and the function of this enzyme was expressed as U/mg protein.

Assay of NO level

Griess's technique was applied to measure the NO in the kidney along with Griess diazotization reaction following conversion of the nitrate to nitrite by nitrate reductase in the supernatant (Tracey et al., 1990). NO level was expressed as nmol/mg protein.

Assay of SOD and GPx activity

The function of SOD and GPx enzymes was measured by the kits following the protocol of the producer (ZellBio GmbH, Germany), and the function of these enzymes was expressed as U/mg protein.

TNF- α and IL-1 β assay

levels of TNF- α and IL-1 β cytokines in the kidney was evaluated using ELISA kits, following the guideline published by the producer (R&D Systems, Inc., Minneapolis, MN, USA).

Histopathological assays

In order to perform histological examination, left kidney from all groups was fixed in formalin (10%) for at least 24h and following preparing the tissue, all tissues were put into paraffin. Routine hematoxylin & eosin (H & E stain) were applied to stain 5 μm sections (Wadie et al., 2021). A light microscope in a blind manner (Nikon Labophot, Japan) was used to study six microscopy Slides per animal and Light microscopic assessment was conducted by authors in a blinded manner for assessment of histological alternations like congestion of RBC and inflammatory cell infiltration.

Statistical Analysis

The Graph Pad Prism version 6.01 (Graph Pad Software, USA) were used to conduct all statistical analyses. Parameters within groups were statistically analyzed using the ANOVA, followed by Tukey's post hoc and P value less than .05 was considered significant. Results were reported as mean $\pm$ standard deviations (SD) of number of experiments (n = 8).

Results

Effects of CP and BBR on serum biochemical parameters

Results indicated the Serum levels of BUN, Cr, NGAL, and KIM-1 were significantly elevated after CP administration in comparison to the control group (all $p < 0.05$), and these increases in the groups received BBR were significantly attenuated than CP group (all $p < 0.05$). The serum levels of serum biochemical parameters in the group treated with berberine alone were similar to controls and there were no significant changes (fig 1 a-d).

Effects of CP and BBR on OS parameters

The impacts of CP and BBR on NO and MDA levels as oxidative parameters are illustrated in fig. 2 (a, b). CP treatment led to a significant increase in the level of NO and MDA in comparison to controls ($p < 0.05$). Although BBR treatment at the dose of 50 mg/kg reduced slightly MDA levels (no significant) but 100 mg/kg of BBR significantly decreased the MDA levels compared with the CP group. Also, BBR treatment (50 and 100 mg/kg) considerable declined NO than the CP group ($p < 0.05$), Furthermore, there weren't any considerable differences among the group received BBR (alone) and the control group.

Effects of CP and BBR on Antioxidants markers

The impacts of BBR on the function of antioxidant enzymes and the GSH content are provided in Fig. 3 (a-d). Results indicated that a single dose of CP administration decreased activity of antioxidants enzymes and GSH level (all $p < 0.05$). Pre-treatment with BBR at the dose of 100 mg/kg significantly increased GPx activity and GSH content compared with the CP group ($p < 0.05$). Moreover, BBR (50 and 100 mg/kg) slightly enhanced CP-stimulated decreased of CAT and SOD activity but there weren't any significantly changes. In addition, the BBR (alone) group didn't show any significant change in comparison with control group.

Effects of CP and BBR on inflammatory parameters

As shown in Fig. 4 (a, b), CP treatment significantly increased IL-1 β and TNF- α levels as inflammatory parameters than controls. Pretreatment with BBR at the dose of 100 mg/kg significantly decreased IL-1 β and TNF- α levels than the CP. Also, the BBR (alone) group didn't show any significant change in comparison with control group.

Effects of CP and BBR on histopathological alternations

Nephrotoxicity induced by CP in mice was further assessed using H&E stained sections. Representative examples of the histological appearance in the experimental groups are shown in (Fig. 5 a-e). The kidney sections from the control and BBR (100mg/kg, alone) groups had a usual structure of the kidney cells (Fig. 5 a and e), but on the other hand, in the CP group the kidney exhibited notable histopathological changes. CP induced extensive injuries such as degeneration of the renal tubules, glomerular atrophy, hemorrhage and inflammatory cell infiltration (Fig. 5 b). While pretreatment with BBR (50 and 100 mg/kg) for seven days declined the occurrence and intensity of histopathological lesions compared to CPs (Fig. 5 c and d). Furthermore, the renal tubules and glomerulus have a nearly normal structure.

Discussion

In this research, the effects of BBR on CP-stimulated nephrotoxicity in mice were investigated. Drug-stimulated nephrotoxicity is a major medical problem and there is a growing number of hospitalized patients who develop a drug-induced renal problem (Hoitsma et al., 1991). Detection of acute kidney injury often is according to serum levels of BUN and Cr that illustrates the filtration capacity of the glomerulus and these are usually the first steps to the diagnosis of renal injury (Salazar, 2014). However, these factors are not very sensitive or specific and can be affected by nonrenal variables independent from kidney injury or malfunction. Some biomarkers such as KIM-1 and NGAL are made predominantly by the injured kidney and seems to be more specific and sensitive (Edelstein, 2017). Our findings confirmed that administration of CP (200 mg/kg) cause nephrotoxicity significantly as indicated by enhanced levels of BUN, Cr, KIM-1 and NGAL. On the other hand, pretreatment with BBR reduced the level of serum markers than CP group. Free radicals are generated in a wide variety of chemicals and medications such as cyclophosphamide and depletes mitochondria enzymatic and non-enzymatic antioxidant defense systems (Halliwell, 2001). In addition, pro-inflammatory cytokines (TNF- α , IL-6, and IL-1 β) are a series of immunoregulatory molecules that control the mucosal immune system. In addition, it worth noting that neutrophils and macrophages intervene epithelial uniformity and are known for their impact on pathogenesis of several health problems (Neurath, 2014). It seems both free radicals and pro-inflammatory cytokines play a crucial role in the toxicity of cyclophosphamide and several studies previously demonstrated that cyclophosphamide in animals and humans induced several kinds of damage such as nephrotoxicity, hepatotoxicity, ovarian toxicity and testicular toxicity (Fraisier et al., 1991). Previous studies have shown that cyclophosphamide caused nephrotoxicity and hepatotoxicity through increasing OS markers such as MDA, NO and inflammatory responses, and depletion in glutathione content, antioxidant enzymes activities (GPx, SOD, CAT, GSH, quinone reductase), DNA strand breaks (Rehman et al., 2012). Our findings showed that CP increases levels of oxidative and inflammatory parameters including MDA, NO, TNF- α , IL-1 β and GSH, GPx, SOD and CAT activities were declined, which is in line with the literature. Also, pretreatment with the antioxidant, BBR, prior to CP results in a decrease in the renal MDA, NO TNF- α , IL-1 β and an elevation in GSH levels and GPx activity. The obtained findings are consistent with other indicating the antioxidant and anti-inflammatory effects caused by BBR.

The exact mechanism underlying the effects of berberine is unclear. However, many studies have shown the beneficial effects of berberine on inflammation and oxidative stress. Previous reports have shown that protective effects of BBR against nephrotoxicity by inhibition of TGF- β /Smad/EMT pathway and activating Nrf2 pathway (Zhang et al., 2016a). The results of this study are consistent with these previous reports and indicated BBR administration significantly affected CP-induced nephrotoxicity in mice via regulation of kidney injury biomarkers in serum, oxidative stress and inflammatory factors in tissue. Kidney histopathological results also were consistent with biochemical assessment and demonstrated the beneficial effect of berberine in structural changes of CP-induced nephrotoxicity in mice.

Conclusion

In summary, the present study demonstrated that BBR alongside with CP in mice can protect renal tissue from CP-induced nephrotoxicity through significantly decreasing the level of BUN, Cr, NGAL and KIM-1 in serum and modifying oxidative, inflammatory parameters and improving histological changes of kidney tissue.

Declarations

Funding

This work was supported by Deputy of Research of Shoushtar University of Medical Sciences, Shoushtar, Iran (Grant number: TRC-9803). I would like to acknowledge Vice Chancellor of Research, Toxicology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, for supporting this work.

Authors' contribution

MK and MAM conceived and designed the study. MAM, HK and ES performed experiments. MAM, MG and ES analyzed data. HK and HRK wrote the manuscript.

All authors read and approved the manuscript and all data were generated in-house and that no paper mill was used.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethics approval

The investigation complies with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication no. 85–23, revised 1996). The investigation complies with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of

Health (NIH Publication no. 85-23, revised 1996). The Animal Ethics Committee of the Ahvaz Jundishapur University of Medical Sciences approved our research protocol (**Ethic code:** IR.BHN.REC.1397.033).

Availability of data and materials

All data generated or analysed during this study are included in this published article [and its supplementary information files].

References

1. Aebi H. (1984) Catalase in vitro. *Methods Enzymol* 105:121-126. [https://doi.org/10.1016/s0076-6879\(84\)05016-3](https://doi.org/10.1016/s0076-6879(84)05016-3)
2. Bradford N. (1976) A rapid and sensitive method for the quantitation microgram quantities of a protein isolated from red cell membranes. *Anal Biochem* 7;72:248-54. <https://doi.org/10.1006/abio.1976.9999>.
3. Crivellari D., Bonetti M., Castiglione-Gertsch M., Gelber R.D., Rudenstam C.-M., Thürlimann B., Price K.N., Coates A.S., Hürny C., Bernhard J.r. (2000) Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. *J Clin Oncol* 18:1412-1422. <https://doi.org/10.1200/JCO.2000.18.7.1412>.
4. Edelstein C.L. (2017) Biomarkers in acute kidney injury. *Biomarkers of Kidney Disease*. 2nd edn., Elsevier Netherlands, pp 241-315.
5. El-Naggar S.A., Alm-Eldeen A.A., Germoush M.O., El-Boray K.F., Elgebaly H.A. (2015) Ameliorative effect of propolis against cyclophosphamide-induced toxicity in mice. *Pharm Biol* 53:235-241. <https://doi.org/10.3109/13880209.2014.914230>.
6. Fraiser L.H., Kanekal S., Kehrer J.P. (1991) Cyclophosphamide toxicity. *Drugs* 42:781-795. <https://doi.org/10.3109/13880209.2014.914230>. <https://doi.org/10.2165/00003495-199142050-00005>.
7. Goudarzi M., Kalantar M., Sadeghi E., Karamallah M.H., Kalantar H. (2021) Protective effects of apigenin on altered lipid peroxidation, inflammation, and antioxidant factors in methotrexate-induced hepatotoxicity. *Naunyn Schmiedeberg Arch Pharmacol* 394:523-531. <https://doi.org/10.1007/s00210-020-01991-2>.
8. Goudarzi M., Khodayar M.J., Hosseini Tabatabaei S.M.T., Ghaznavi H., Fatemi I., Mehrzadi S. (2017) Pretreatment with melatonin protects against cyclophosphamide-induced oxidative stress and renal damage in mice. *Fundam clin pharmacol* 31:625-635. <https://doi.org/10.1111/fcp.12303>.
9. Halliwell B. (2001) Free radicals and other reactive species in disease. e LS.<https://doi.org/10.1038/npg.els.0002269> Hamsa T., Kuttan G. (2011) Protective role of Ipomoea obscura (L.) on cyclophosphamide-induced uro-and nephrotoxicities by modulating antioxidant

- status and pro-inflammatory cytokine levels. *Inflammopharmacology* 19:155-167.
<https://dio.org/10.1007/s10787-010-0055-3>.
10. Hoitsma A.J., Wetzels J.F., Koene R.A. (1991) Drug-induced nephrotoxicity. *Drug saf* 6:131-147.
<https://dio.org/10.2165/00002018-199106020-00004>.
 11. Kalantar H., Sabetkasaei M., Shahriari A., Haj Molla Hoseini M., Mansouri S., Kalantar M., Kalantari A., Khazaei Poul Y., Labibi F., Moini-Zanjani T. (2016) The effect of rapamycin on oxidative stress in MCF-7 and MDA MB-231 human breast cancer cell lines. *Jundishapur J Nat Pharm Prod* 11(3):e38177. <https://dio.org/10.17795/jjnpp-38177>.
 12. Kuo C.-L., Chi C.-W., Liu T.-Y. (2004) The anti-inflammatory potential of berberine in vitro and in vivo. *Cancer lett* 203:127-137. <https://dio.org/10.1016/j.canlet.2003.09.002>.
 13. Lawson M., Vasilaras A., De Vries A., Mactaggart P., Nicol D. (2008) Urological implications of cyclophosphamide and ifosfamide. *Scand J urol nephrol* 42:309-317.
<https://dio.org/10.1080/00365590701570953>.
 14. Li Z., Geng Y.-N., Jiang J.-D., Kong W.-J. (2014) Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus. *Evid Based Complement Alternat Med* 2014;2014:289264. <https://dio.org/10.1155/2014/289264>.
 15. Lou T., Zhang Z., Xi Z., Liu K., Li L., Liu B., Huang F. (2011) Berberine inhibits inflammatory response and ameliorates insulin resistance in hepatocytes. *Inflammation* 34:659-667.
<https://dio.org/10.1007/s10753-010-9276-2>.
 16. Mahmoud A.M., Abdel-Rahman M.M., Bastawy N.A., Eissa H.M. (2017) Modulatory effect of berberine on adipose tissue PPAR γ , adipocytokines and oxidative stress in high fat diet/streptozotocin-induced diabetic rats. *J. Appl. Pharm. Sci* 7:1-10.
<https://dio.org/10.7324/JAPS.2017.70401>
 17. Moore K., Roberts L.J. (1998) Measurement of lipid peroxidation. *Free Radic Res* 28:659-671.
<https://dio.org/10.3109/10715769809065821>.
 18. Neurath M.F. (2014) Cytokines in inflammatory bowel disease. *Nat Rev Immunol* 14:329-342.
<https://dio.org/10.1038/nri3661>
 19. Perini P., Calabrese M., Rinaldi L., Gallo P. (2007) The safety profile of cyclophosphamide in multiple sclerosis therapy. *Expert opin drug saf* 6:183-190. <https://dio.org/10.1517/14740338.6.2.183>.
 20. Rehman M.U., Tahir M., Ali F., Qamar W., Lateef A., Khan R., Quaiyoom A., Sultana S. (2012) Cyclophosphamide-induced nephrotoxicity, genotoxicity, and damage in kidney genomic DNA of Swiss albino mice: the protective effect of Ellagic acid. *Mol Cell Biochem* 365:119-127.
<https://dio.org/10.1007/s11010-012-1250-x>
 21. Riddles P.W., Blakeley R.L., Zerner B. (1979) Ellman's reagent: 5, 5'-dithiobis (2-nitrobenzoic acid)—a reexamination. *Anal Biochem* 94:75-81. [https://dio.org/10.1016/0003-2697\(79\)90792-9](https://dio.org/10.1016/0003-2697(79)90792-9).
 22. Rodriguez-Antona C., Ingelman-Sundberg M. (2006) Cytochrome P 450 pharmacogenetics and cancer. *Oncogene* 25:1679-1691. <https://dio.org/10.1038/sj.onc.1209377>.

23. Salazar J.H. (2014) Overview of urea and creatinine. *Lab Med* 45:19-20.
<https://doi.org/10.1309/LM920SBNZPJRJGUT>
24. Stankiewicz A., Skrzydlewska E., Makiela M. (2002) Effects of amifostine on liver oxidative stress caused by cyclophosphamide administration to rats. *Drug metabol drug interact* 19:67-82.
<https://doi.org/10.1515/dmdi.2002.19.2.67>.
25. Sun Y., Xun K., Wang Y., Chen X. (2009) A systematic review of the anticancer properties of berberine, a natural product from Chinese herbs. *Anticancer drugs* 20:757-769.
<https://doi.org/10.1097/CAD.0b013e328330d95b>.
26. Tracey W.R., Linden J., Peach M.J., Johns R.A. (1990) Comparison of spectrophotometric and biological assays for nitric oxide (NO) and endothelium-derived relaxing factor (EDRF): nonspecificity of the diazotization reaction for NO and failure to detect EDRF. *Pharmacology Exp Ther* 252:922-928.
27. Wadie W., Mohamed A.H., Masoud M.A., Rizk H.A., Sayed H.M. (2021) Protective impact of lycopene on ethinylestradiol-induced cholestasis in rats. *Naunyn Schmiedebergs Arch Pharmacol* 394:447-455. <https://doi.org/10.1007/s00210-020-01980-5>
28. Wahlang B., Falkner K.C., Cave M.C., Prough R.A. (2015) Role of cytochrome P450 monooxygenase in carcinogen and chemotherapeutic drug metabolism. *Adv Pharmacol* 74:1-33.
<https://doi.org/10.1016/bs.apha.2015.04.004>.
29. Zhang S., Zhang B., Dai W., Zhang X. (2011) Oxidative damage and antioxidant responses in *Microcystis aeruginosa* exposed to the allelochemical berberine isolated from golden thread. *J plant physiol* 168:639-643. <https://doi.org/10.1016/j.jplph.2010.10.005>.
30. Zhang X., He H., Liang D., Jiang Y., Liang W., Chi Z.-H., Ma J. (2016a) Protective effects of berberine on renal injury in streptozotocin (STZ)-induced diabetic mice. *Int J Mol Sci* 17:1327.
<https://doi.org/10.3390/ijms17081327>.
31. Zhang Z., Li X., Li F., An L. (2016b) Berberine alleviates postoperative cognitive dysfunction by suppressing neuroinflammation in aged mice. *Int Immunopharmacol* 38:426-433. <https://doi.org/10.1016/j.intimp.2016.06.031>
32. Zhou J.-Y., Zhou S.-W. (2011) Protective effect of berberine on antioxidant enzymes and positive transcription elongation factor b expression in diabetic rat liver. *Fitoterapia* 82:184-189.
<https://doi.org/10.1016/j.fitote.2010.08.019>.

Figures

Figure 1

Effects of CP and BBR on serum biochemical parameters. Values are mean $\pm$ SD (n = 8). ANOVA and Tukey's tests were used for comparisons. *Significant difference in comparison with the control group ($p < 0.05$). #Significant difference in comparison with the CP group ($p < 0.05$). CP: Cyclophosphamide, BBR: Berberine, BUN: Blood urea nitrogen, Cr: Creatinine, KIM-1: Kidney injury molecule-1, NGAL: Neutrophil gelatinase-associated lipocalin.

Figure 2

Effects of CP and BBR on oxidative stress parameters. Values are mean $\pm$ SD (n = 8). ANOVA and Tukey's tests were used for comparisons. *Significant difference in comparison with the control group ($p < 0.05$). #significant difference in comparison with the CP group ($p < 0.05$). CP: Cyclophosphamide, BBR: Berberine, MDA: Malondialdehyde, NO: Nitric oxide.

Figure 3

Effects of CP and BBR on antioxidants markers. Values are mean $\pm$ SD ($n = 8$). ANOVA and Tukey's tests were used for comparisons. *Significant difference in comparison with the control group ($p < 0.05$). #significant difference in comparison with the sham group (CP group) ($p < 0.05$). CP: Cyclophosphamide, BBR: Berberine GSH: Glutathione, GPx: Glutathione peroxidase, SOD: Superoxide dismutase: CAT: Catalase.

Figure 4

Effects of CP and BBR on inflammatory parameters. Values are mean $\pm$ SD (n = 8). ANOVA and Tukey's tests were used for comparisons. *Significant difference in comparison with the control group ($p < 0.05$) #significant difference in comparison with the CP group ($p < 0.05$) CP: Cyclophosphamide, BBR: Berberine, TNF- α : Tumor necrosis factor- α , IL-1 β : Interleukin 1 beta.

Figure 5

Histopathological observations (kidney sections stained with Hematoxylin & Eosin, magnification X 200) showing effects of berberine on cyclophosphamide-induced renal toxicity. Fig. 5a: Control group, Fig. 5b: Cyclophosphamide group, Fig. 5c: Berberine (50 mg/kg)+ Cyclophosphamide group, Fig. 5d: Berberine (100 mg/kg)+Cyclophosphamide group, Fig. 5e: Berberine (100 mg/kg, alone). C: Congestion of RBC, I: Infiltration of inflammatory cells.